Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04782856 · ClinicalTrials.gov registry record · Phase 2
Energy Metabolism in Thyroidectomized Patients
A Phase 2 study of Thyroid Cancer and Hypothyroidism, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT04782856: Completed Phase 2 study of Thyroid Cancer and Hypothyroidism, sponsored by Virginia Commonwealth University.
NCT04782856 is a Phase 2 study of Thyroid Cancer and Hypothyroidism that has completed, run by Virginia Commonwealth University. The registered enrollment target is 13 participants, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04782856, a Phase 2 study of Thyroid Cancer and Hypothyroidism, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to measure the changes in energy metabolism (how the body burns energy), cardiovascular function (heart function), and lipid metabolism (cholesterol break down and building) before and after thyroidectomy (surgical removal of thyroid gland) in response to two approved therapies for hypothyroidism: levothyroxine (LT4) or Liothyronine/levothyroxine (LT3/LT4) combination therapy.
Primary Outcome
Weight will be measured in kilograms using a stadiometer
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Levothyroxine
- DRUG Liothyronine
Study Locations (1)
Virginia
- Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2023-04-19 |
| Phase | Phase 2 |
What the finished NCT04782856 record still lists
NCT04782856 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04782856 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT04782856 about?
NCT04782856 is a clinical study titled "Energy Metabolism in Thyroidectomized Patients". The purpose of this research study is to measure the changes in energy metabolism (how the body burns energy), cardiovascular function (heart function), and lipid metabolism (cholesterol break down and building) before and after thyroidectomy (surgical removal of thyroid gland) in response to two ap...
What is the current status of trial NCT04782856?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2020-10-28. Estimated completion is 2023-04-19.
What conditions does trial NCT04782856 study?
This clinical trial studies the following conditions: Thyroid Cancer, Hypothyroidism, Thyroid Goiter.
What interventions are being tested in trial NCT04782856?
The interventions under investigation include: Placebo (DRUG), Levothyroxine (DRUG), Liothyronine (DRUG).
Who is sponsoring clinical trial NCT04782856?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04782856 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04782856's enrollment target sits among peer trials
13 39th of 46 higher than 8 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI